HAON Life Science’s Post

We also had the opportunity to sit down with Moayed Hamza and Mark O’Neill FCA from HAON Life Science, which develops investigational allogeneic candidates for neurologic, rare and other serious diseases. Their first focus indication is neonatal HIE – a type of newborn brain injury – that according to Nature has an incidence that varies between 1 and 3 per 1000 live births in developed countries and 2.3 to 30.6 per 1000 live births in developing countries. Yet, there are no current treatments available aside from cooling. Hamza and O'Neill tells BioStock that their platform is applicable in multiple neurodegenerative diseases, but that they aim for a first approval in neonatal HIE due to its high unmet medical need, lack of competition in the market and thus presents an opportunity for accelerated approval. Hear more about their progress in our interview!